Navigation Links
Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
Date:4/3/2008

hers, that future preclinical and clinical trials may not replicate results seen in previous clinical trials; that pre-clinical studies described in this press release may fail to indicate that the immunostimulant patch improves the immune response or reduces the necessary vaccine dosage by as much as anticipated; that the timing and effectiveness of the pre-clinical are dependent on sufficient coordination and cooperation with Merck and third parties; that potential collaborators, including Merck, may determine to wait for additional preclinical and/or clinical data prior to entering into a collaboration or may be unwilling to collaborate on terms Iomai deems acceptable; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates using the Iomai's immunostimulant patch; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the other risks identified under the heading "Risk Factors" in Iomai's annual report on Form 10-K for the year ended December 31, 2007 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company's filings for a discussion of these and other risks and uncertainties which are filed with the Securities and Exchange Commission and available at http://www.sec.gov. All statements in this press release only speak as of its date, and Iomai undertakes no obligation to update or revise the statements.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
4. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... Median time to pain progression is 66.1 weeks ... the placebo arm --,Hazard ratio of 0.64 (95% ... relative risk of pain progression, MARTINSRIED/MUNICH, Germany, May ... -- GPC Biotech AG and,Pharmion Corporation today announced ...
... analysis shows nearly nine out of ten patients ... of 12 months, WASHINGTON, D.C., May 22, 2007 ... extension study (303),presented at the British Society of ... showed Shire plc's,Lialda(mesalamine) is well tolerated in mild ...
Cached Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... As reported by the New ... a significant number of severe adverse events such as ... even death from the highly-promoted and costly immune-system drug, ... report , a regulatory filing revealed that the ... was almost 14% of prescriptions, up from 9.1% in ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... growth during the five years to 2014 on the ... Regulations of 2010 prompted farmers to dedicate a larger ... in ethanol production. More specifically, the regulations required the ... Similarly, rapidly expanding biofuel production in the United States ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a reliable source ... Mountain View, CA. Over the years Luke Bryan has been ... only does he do well at award shows, but each summer, ... most anticipated tours of the genre and this summer is more ... can compare to the popularity and success that is currently entitled ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... in ... underserved areas, WOODLAND HILLS, Calif., Dec. 11 ... in end of,year donations to various food banks throughout California. An unrestricted,check ... California to assist vulnerable populations., Blue Cross employees will visit each ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage ... cancer and inflammatory diseases, today,announced that the ... accepted its,Investigational New Drug (IND) application for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ...
... WARSAW, Ind., Dec. 11 Zimmer Holdings, Inc.,(NYSE: ... industry, announced,today that its Premarket Approval (PMA) application for ... the Food and Drug,Administration., "A number of orthopaedic ... be one of only two companies that can offer ...
... Recent developments regarding,North Carolina,s organ and tissue donation ... to hire Corder Philips to aid in the,campaign ... developments include a grant received from the License ... update their online,registry and increase outreach efforts by ...
... Calif., Dec. 11 Varian Medical,Systems (NYSE: VAR ... the company,s Annual Meeting of Stockholders for February 14,2008 ... meeting will be held at,the Sheraton Palo Alto, 625 ... The meeting will be webcast by CCBN and ...
... regions activated by beliefs and human feelings, study shows ... disbelief and uncertainty activate distinct areas of the brain, ... online in the Annals of Neurology . ... was monitored using functional magnetci resonance imaging (fMRI) while ...
Cached Medicine News:Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 3Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 4Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 2Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 3Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 4Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Personal Convictions May Control Both Behavior and Emotions 2
... an innovative, quick and easy automated ... 60% less space on your laboratory ... this amazingly easy-to-use, one-hand system, you ... whole range of Diamond Tips. All ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: